Cancer in Crohn's Disease patients treated with infliximab: A long-term multicenter matched pair study

Mario Cottone, Mario Cottone, Livia Biancone, Carmelina Petruzziello, Erika Angelucci, Sara Onali, Francesca Zorzi, Filippo Mocciaro, Gabriele Riegler, Anna Kohn, Giuseppe Sica, Marco Daperno, Gianmichele Meucci, Fernando Rizzello, Claudio Papi, Renata D'Incã, Fabiana Castiglione, Sandro Ardizzone, Ambrogio Orlando, Francesco PalloneEmma Calabrese

Risultato della ricerca: Article

36 Citazioni (Scopus)

Abstract

AbstractThe long-term risk of neoplasia in Crohn's disease (CD) patients treated with infliximab is undefined. The aim was to assess, in a multicenter, matched-pair study, whether infliximab use in CD is associated with an increased frequency of neoplasia in the long term.A multicenter, long-term, matched-pair study was conducted in 12 referral inflammatory bowel disease (IBD) centers. An initial cohort of 808 CD patients, including 404 infliximab-treated (CD-IFX) and 404 matched CD controls never treated with infliximab (CD-C) studied from 1999 to 2004, was followed up for an additional 4 years (2004-2008). Cases and controls were matched for: sex, age (±5 years), CD site, follow-up (±5 years), immunosuppressant use, and CD duration (±5 years). From 1999 to 2008 the frequency and characteristics of neoplasia were compared between CD-IFX and CD-C.In 2008, 591 patients (304 CD-IFX, 287 CD-C) were in follow-up. Matched couples included 442 patients: 221 CD-IFX and 221 CD-C (median follow-up, months: 72, range 48-114 versus 75, range 44-114). From 1999 to 2008 the frequency of neoplasia among the 591 patients did not differ between CD-IFX (12/304; 3.94%) and CD-C (12/287; 4.19%; P = 0.95). A comparable frequency of neoplasia was also observed between the 221 matched couples (CD-IFX: 8/221; 3.61% versus CD-C: 9/221; 4.07%; P = 1). No specific histotype of cancer appeared associated with infliximab use.The frequency of neoplasia was comparable in an adult population of CD patients treated or not with infliximab, matched for clinical variables and followed up for a median of 6 years.
Lingua originaleEnglish
pagine (da-a)758-766
Numero di pagine9
RivistaInflammatory Bowel Diseases
Volume17
Stato di pubblicazionePublished - 2011

Fingerprint

Crohn Disease
Neoplasms
Infliximab
Immunosuppressive Agents

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Gastroenterology

Cita questo

Cottone, M., Cottone, M., Biancone, L., Petruzziello, C., Angelucci, E., Onali, S., ... Calabrese, E. (2011). Cancer in Crohn's Disease patients treated with infliximab: A long-term multicenter matched pair study. Inflammatory Bowel Diseases, 17, 758-766.

Cancer in Crohn's Disease patients treated with infliximab: A long-term multicenter matched pair study. / Cottone, Mario; Cottone, Mario; Biancone, Livia; Petruzziello, Carmelina; Angelucci, Erika; Onali, Sara; Zorzi, Francesca; Mocciaro, Filippo; Riegler, Gabriele; Kohn, Anna; Sica, Giuseppe; Daperno, Marco; Meucci, Gianmichele; Rizzello, Fernando; Papi, Claudio; D'Incã, Renata; Castiglione, Fabiana; Ardizzone, Sandro; Orlando, Ambrogio; Pallone, Francesco; Calabrese, Emma.

In: Inflammatory Bowel Diseases, Vol. 17, 2011, pag. 758-766.

Risultato della ricerca: Article

Cottone, M, Cottone, M, Biancone, L, Petruzziello, C, Angelucci, E, Onali, S, Zorzi, F, Mocciaro, F, Riegler, G, Kohn, A, Sica, G, Daperno, M, Meucci, G, Rizzello, F, Papi, C, D'Incã, R, Castiglione, F, Ardizzone, S, Orlando, A, Pallone, F & Calabrese, E 2011, 'Cancer in Crohn's Disease patients treated with infliximab: A long-term multicenter matched pair study', Inflammatory Bowel Diseases, vol. 17, pagg. 758-766.
Cottone, Mario ; Cottone, Mario ; Biancone, Livia ; Petruzziello, Carmelina ; Angelucci, Erika ; Onali, Sara ; Zorzi, Francesca ; Mocciaro, Filippo ; Riegler, Gabriele ; Kohn, Anna ; Sica, Giuseppe ; Daperno, Marco ; Meucci, Gianmichele ; Rizzello, Fernando ; Papi, Claudio ; D'Incã, Renata ; Castiglione, Fabiana ; Ardizzone, Sandro ; Orlando, Ambrogio ; Pallone, Francesco ; Calabrese, Emma. / Cancer in Crohn's Disease patients treated with infliximab: A long-term multicenter matched pair study. In: Inflammatory Bowel Diseases. 2011 ; Vol. 17. pagg. 758-766.
@article{f80504efee3e4e0cab98ac2efbb7f1bc,
title = "Cancer in Crohn's Disease patients treated with infliximab: A long-term multicenter matched pair study",
abstract = "AbstractThe long-term risk of neoplasia in Crohn's disease (CD) patients treated with infliximab is undefined. The aim was to assess, in a multicenter, matched-pair study, whether infliximab use in CD is associated with an increased frequency of neoplasia in the long term.A multicenter, long-term, matched-pair study was conducted in 12 referral inflammatory bowel disease (IBD) centers. An initial cohort of 808 CD patients, including 404 infliximab-treated (CD-IFX) and 404 matched CD controls never treated with infliximab (CD-C) studied from 1999 to 2004, was followed up for an additional 4 years (2004-2008). Cases and controls were matched for: sex, age (±5 years), CD site, follow-up (±5 years), immunosuppressant use, and CD duration (±5 years). From 1999 to 2008 the frequency and characteristics of neoplasia were compared between CD-IFX and CD-C.In 2008, 591 patients (304 CD-IFX, 287 CD-C) were in follow-up. Matched couples included 442 patients: 221 CD-IFX and 221 CD-C (median follow-up, months: 72, range 48-114 versus 75, range 44-114). From 1999 to 2008 the frequency of neoplasia among the 591 patients did not differ between CD-IFX (12/304; 3.94{\%}) and CD-C (12/287; 4.19{\%}; P = 0.95). A comparable frequency of neoplasia was also observed between the 221 matched couples (CD-IFX: 8/221; 3.61{\%} versus CD-C: 9/221; 4.07{\%}; P = 1). No specific histotype of cancer appeared associated with infliximab use.The frequency of neoplasia was comparable in an adult population of CD patients treated or not with infliximab, matched for clinical variables and followed up for a median of 6 years.",
keywords = "Cancer, Inflammatory bowel disease, Infliximab",
author = "Mario Cottone and Mario Cottone and Livia Biancone and Carmelina Petruzziello and Erika Angelucci and Sara Onali and Francesca Zorzi and Filippo Mocciaro and Gabriele Riegler and Anna Kohn and Giuseppe Sica and Marco Daperno and Gianmichele Meucci and Fernando Rizzello and Claudio Papi and Renata D'Inc{\~a} and Fabiana Castiglione and Sandro Ardizzone and Ambrogio Orlando and Francesco Pallone and Emma Calabrese",
year = "2011",
language = "English",
volume = "17",
pages = "758--766",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Cancer in Crohn's Disease patients treated with infliximab: A long-term multicenter matched pair study

AU - Cottone, Mario

AU - Cottone, Mario

AU - Biancone, Livia

AU - Petruzziello, Carmelina

AU - Angelucci, Erika

AU - Onali, Sara

AU - Zorzi, Francesca

AU - Mocciaro, Filippo

AU - Riegler, Gabriele

AU - Kohn, Anna

AU - Sica, Giuseppe

AU - Daperno, Marco

AU - Meucci, Gianmichele

AU - Rizzello, Fernando

AU - Papi, Claudio

AU - D'Incã, Renata

AU - Castiglione, Fabiana

AU - Ardizzone, Sandro

AU - Orlando, Ambrogio

AU - Pallone, Francesco

AU - Calabrese, Emma

PY - 2011

Y1 - 2011

N2 - AbstractThe long-term risk of neoplasia in Crohn's disease (CD) patients treated with infliximab is undefined. The aim was to assess, in a multicenter, matched-pair study, whether infliximab use in CD is associated with an increased frequency of neoplasia in the long term.A multicenter, long-term, matched-pair study was conducted in 12 referral inflammatory bowel disease (IBD) centers. An initial cohort of 808 CD patients, including 404 infliximab-treated (CD-IFX) and 404 matched CD controls never treated with infliximab (CD-C) studied from 1999 to 2004, was followed up for an additional 4 years (2004-2008). Cases and controls were matched for: sex, age (±5 years), CD site, follow-up (±5 years), immunosuppressant use, and CD duration (±5 years). From 1999 to 2008 the frequency and characteristics of neoplasia were compared between CD-IFX and CD-C.In 2008, 591 patients (304 CD-IFX, 287 CD-C) were in follow-up. Matched couples included 442 patients: 221 CD-IFX and 221 CD-C (median follow-up, months: 72, range 48-114 versus 75, range 44-114). From 1999 to 2008 the frequency of neoplasia among the 591 patients did not differ between CD-IFX (12/304; 3.94%) and CD-C (12/287; 4.19%; P = 0.95). A comparable frequency of neoplasia was also observed between the 221 matched couples (CD-IFX: 8/221; 3.61% versus CD-C: 9/221; 4.07%; P = 1). No specific histotype of cancer appeared associated with infliximab use.The frequency of neoplasia was comparable in an adult population of CD patients treated or not with infliximab, matched for clinical variables and followed up for a median of 6 years.

AB - AbstractThe long-term risk of neoplasia in Crohn's disease (CD) patients treated with infliximab is undefined. The aim was to assess, in a multicenter, matched-pair study, whether infliximab use in CD is associated with an increased frequency of neoplasia in the long term.A multicenter, long-term, matched-pair study was conducted in 12 referral inflammatory bowel disease (IBD) centers. An initial cohort of 808 CD patients, including 404 infliximab-treated (CD-IFX) and 404 matched CD controls never treated with infliximab (CD-C) studied from 1999 to 2004, was followed up for an additional 4 years (2004-2008). Cases and controls were matched for: sex, age (±5 years), CD site, follow-up (±5 years), immunosuppressant use, and CD duration (±5 years). From 1999 to 2008 the frequency and characteristics of neoplasia were compared between CD-IFX and CD-C.In 2008, 591 patients (304 CD-IFX, 287 CD-C) were in follow-up. Matched couples included 442 patients: 221 CD-IFX and 221 CD-C (median follow-up, months: 72, range 48-114 versus 75, range 44-114). From 1999 to 2008 the frequency of neoplasia among the 591 patients did not differ between CD-IFX (12/304; 3.94%) and CD-C (12/287; 4.19%; P = 0.95). A comparable frequency of neoplasia was also observed between the 221 matched couples (CD-IFX: 8/221; 3.61% versus CD-C: 9/221; 4.07%; P = 1). No specific histotype of cancer appeared associated with infliximab use.The frequency of neoplasia was comparable in an adult population of CD patients treated or not with infliximab, matched for clinical variables and followed up for a median of 6 years.

KW - Cancer

KW - Inflammatory bowel disease

KW - Infliximab

UR - http://hdl.handle.net/10447/53764

M3 - Article

VL - 17

SP - 758

EP - 766

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

ER -